Navigation Links
Innovex to Promote PharmaMar's Yondelis(R) Cancer Treatment
Date:12/3/2007

PharmaMar, Innovex to build Yondelis(R) sales network across Western Europe

BRACKNELL, United Kingdom, Dec. 3 /PRNewswire/ -- Innovex today announced a services agreement with PharmaMar, a subsidiary of Zeltia SA, to recruit, train and deploy a specialized oncology sales team in Western Europe to promote Yondelis(R), PharmaMar's treatment for soft tissue sarcoma. PharmaMar, which holds the marketing authorization, will be responsible for marketing the drug.

Innovex will initially deploy regional unit heads and key account managers in the United Kingdom, Germany, France, Spain and Italy to promote Yondelis. The project will be coordinated across these countries by PharmaMar and an Innovex European project director.

Innovex, a unit of Quintiles Transnational Corp., is the leading global commercial solutions provider to the pharmaceutical, biotech and medical device industries.

"Innovex's proven ability to build and launch sales forces across a multi- country region was a key factor in PharmaMar's selecting us to build its sales network for Yondelis in Western Europe," said Hywel Evans, Global President, Innovex. "This is testament to our ability to rapidly recruit, train and deploy high-performing specialty sales representatives who ensure our customers achieve their sales objectives."

Yondelis was launched Sept. 19 by PharmaMar in the United Kingdom and Germany, following its approval by the European Medicines Agency for use in the treatment of soft tissue sarcoma.

Alfonso Casal, Commercial Director, PharmaMar, said: "This agreement with Innovex means we can optimize the launch of Yondelis across five Western European countries as registration and reimbursement allows. Innovex has demonstrated that they have the ability to recruit high caliber, experienced oncology representatives that understand the marketplace and have the technical expertise required in the oncology market.

"Using Innovex services also gives us both flexibility and scalability in our future sales force deployment."

The project will be overseen by a joint steering committee of representatives from PharmaMar and Innovex.

About Innovex

Innovex is the sales and marketing unit of Quintiles Transnational Corp. Innovex is a leading commercial solutions provider that offers sales and marketing services designed to accelerate the success of pharmaceutical, biotechnology and medical device products. Innovex operates in multiple geographies and ensures that high quality sales solutions can be provided where the customer needs them -- locally, regionally and across multiple countries. For more information, visit http://www.innovex.com.

About Quintiles

Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the biotechnology and healthcare industries. With 20,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at http://www.qtrn.com.

About PharmaMar

PharmaMar is the world leader biopharmaceutical company of the Zeltia Group, committed to advancing the treatment of cancer through the discovery and development of new marine-derived medicines. PharmaMar has five novel compounds: Yondelis(r) has received Authorization for Commercialization from the European Commission for advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or for patients who are unsuited to receive these agents. Yondelis(r) is also in phase III for ovarian cancer and phase II for prostate, breast and pediatric cancers. Aplidin(r), Kahalalide F, Zalypsis(r) and PM02734 are in clinical trials. PharmaMar also has a rich pipeline of preclinical candidates, and a strong R&D program.


'/>"/>
SOURCE Innovex
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. ForceLogix, Innovex Win Sales Operational Performance Award
2. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
3. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
4. Enzyme promotes fat formation
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... ... August 11, 2017 , ... A staple in the community for ... will incorporate important key elements including a new digital marketing strategy and updated logo. ... them, Bill Miller has partnered with the South Texas Blood & Tissue Center for ...
(Date:8/11/2017)... (PRWEB) , ... August 11, 2017 , ... ... food production, and, in particular, more natural alternatives to synthetic ingredients,” said Matt ... of Third Wave, with the established manufacturing presence and know-how of Biorigin will ...
(Date:8/10/2017)... ... August 09, 2017 , ... Teachers from three Philadelphia ... August 14th through the 16th, the University City Science Center will kick off ... 2016, provides Philadelphia-based middle school educators an opportunity for professional development related to ...
(Date:8/10/2017)... ... ... Each year in the United States more than 300,000 people are hospitalized for ... even worse, the one-year mortality rate is high, ranging from 12 percent to 37 ... Medical Center (Sacramento) and Second Xiangya Hospital of the Central-South University (Hunan, China) might ...
Breaking Biology Technology:
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):